Gary Peters is a Michigan senator in the middle of a Democratic primary fight, defending a seat that The Detroit News just weighed in on, and releasing public statements at a pace that suggests his press shop is fully caffeinated. Meanwhile, on April 23rd of this year, he was also busy doing something the press releases don't mention: selling Corteva Agriscience and buying PepsiCo and J.M. Smucker in the same sitting. Peters sits on the Senate Appropriations subcommittee that funds the FDA and agriculture programs. Two of those three April trades sit inside that jurisdiction. The filings are public. The committee assignments are public. The calendar is what it is.
The Political Moment
Peters is navigating a Democratic primary in Michigan, a swing state where he's held his Senate seat since 2015. The Detroit News editorial board has entered the conversation, weighing in on who should carry the Democratic banner in what's shaping up as a competitive cycle. On the social side, a small cluster of Bluesky posts this week puts Peters in the frame as a workhorse senator, with at least one user crediting him alongside Amy Klobuchar as among the more effective members of the chamber. Another noted he'd returned a blue slip allowing district court nominees to advance in Michigan, which is either good governance or the kind of procedural move you do when you're trying to shore up your reputation mid-campaign. Probably both.
Peters also released a statement this week that generated enough attention to land in Google News. The substance of that statement is not what concerns us here. What concerns us is the full picture of Peters in 2026: senator, primary candidate, Appropriations subcommittee member, and an active participant in the stock market whose disclosed trades land squarely inside his own committee's jurisdiction.
Three Trades, One Day, Two Jurisdictions
On April 23, 2026, Peters filed three trades. All on the same date. Per his disclosure record on Blind Trust:
- Sold Corteva Agriscience (CTVA): $15,000-$50,000. Corteva is a crop science and seed company, firmly in the agriculture lane.
- Bought PepsiCo (PEP): $15,000-$50,000. PepsiCo is a food and beverage conglomerate subject to FDA oversight.
- Bought J.M. Smucker (SJM): $1,000-$15,000. Smucker makes Jif, Folgers, and Milk-Bone, among other things. Also subject to FDA and agriculture policy.
Peters sits on the Senate Appropriations subcommittee covering Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. That's the subcommittee that literally writes the funding lines for the FDA and the USDA. Corteva, PepsiCo, and Smucker all live inside that remit.
The Corteva sale is the one that jumps out. Per the alpha record, that trade produced a 30-day excess return of negative 5.6% against the S&P 500. Peters sold, the stock kept dropping relative to the index. Whether that makes him a good seller or a lucky one is a question the data can't answer. But it's the single trade in this 90-day window that sits at the intersection of committee oversight and a meaningful price move.
The Alpha Record: Read It Honestly
Across 9 scored trades in the full sample, Peters is 5-for-9 on generating positive 30-day alpha. The mean 30-day alpha across all 9 trades is negative 3.4%. That's a senator whose portfolio, in aggregate, has trailed the market over the 30 days following each disclosed trade.
The best individual trade in the sample was a January 12, 2026 purchase of Stanley Black and Decker at $15,000-$50,000, which generated 9.2% positive alpha over 30 days. No committee overlap flagged on that one. Same for a WPC purchase on the same date, which produced 7.3% alpha. Both look like decent calls. Neither carries an oversight angle.
The worst trade in the sample is not close. An October 7, 2025 sale of Organon (OGN) in the $1,000-$15,000 range produced negative 39.9% alpha over 30 days. That's a sale of a women's health and biosimilars spinoff that then, apparently, recovered sharply relative to the index after Peters sold it. No committee overlap on that one either. Just a bad trade.
The pattern across the four committee-overlap trades is more mixed than the headline trades suggest. The Verizon purchase in December 2025 (Telecommunications subcommittee overlap) produced negative 1.4% alpha. The Intel sale the same month (Technology overlap) produced negative 5.8% alpha, meaning Peters sold and Intel continued to drop, which is a negative alpha outcome for a sale. The PepsiCo buy in April sits at essentially flat, 0.4% positive alpha, 30 days out.
The math: four committee-overlap trades, mixed results, mean alpha that lags the index. If there's an informational edge buried in the committee seat, it hasn't shown up in the returns.
The Bigger Question the Data Can't Answer
Here's what the STOCK Act requires: disclosure within 45 days. Here's what it doesn't require: divestiture, recusal, abstaining from votes that affect your holdings, or any public explanation of why you made the trade. Members are free to hold stocks in sectors they regulate, vote on legislation affecting those sectors, and sit in closed Appropriations markups where funding decisions get made, all while maintaining an active brokerage account. The disclosure requirement is the whole enforcement mechanism. That's the rule.
Peters voted Yea on the 21st Century ROAD to Housing Act on June 22, 2026. He voted to invoke cloture on the same bill on June 18. He voted Yea on the motion to proceed on June 16. Housing legislation doesn't cross into his Appropriations agriculture subcommittee remit, so there's no overlap angle there. Those are floor votes, not committee votes, and the brief data shows no flagged overlap. Worth noting only because it illustrates the difference between a floor vote (every senator has one) and a committee position (Peters has specific oversight power in agriculture and FDA).
The Iran War Powers votes in late June are similarly outside the committee-overlap frame. Peters voted Yea on multiple motions to constrain military hostilities with Iran; that's Armed Services and Foreign Relations territory, and while Peters sits on Armed Services, the data shows no flagged trade overlap there either.
What the Portfolio Looks Like as a Character Study
Pull back and look at the full picture. Peters sits on Appropriations Agriculture and FDA. He owns positions in PepsiCo and J.M. Smucker, two companies whose product lines run directly through FDA labeling, nutrition policy, and USDA program funding. He recently exited Corteva, an ag-sector crop science company, on the same day he entered those two consumer food names. The rotation is from upstream agriculture to downstream consumer food brands, both sectors squarely under his committee's funding authority.
Is that a sophisticated read on ag-sector dynamics? Is it a financial advisor's call? Is it a tax-timing move? The disclosure filing doesn't say. It never does. The filing just shows the trade, the date, and the range. What it doesn't show is the conversation that preceded it.
Peters's overall alpha record is a minus. Five wins in nine tries, negative 3.4% mean. By that measure, the portfolio is not beating the market. But the question It's about whether the same person writing USDA and FDA appropriations lines should be holding positions in companies whose revenues depend on what those lines say.
The receipts are public. Make of them what you make of them.